You Searched For: Enzo Life Sciences

Catalog Number: (89165-448)

Supplier: Enzo Life Sciences

Description: Produced in E. coli. Human BAP1 is fused at the N-terminus to a His-tag.

Catalog Number: (89156-714)

Supplier: Enzo Life Sciences

Description: Nicotinic acetylcholine receptor ligand.

Catalog Number: (89152-774)

Supplier: Enzo Life Sciences

Description: TLR4 activator.

Supplier: Enzo Life Sciences

Description: PKC inhibitor

Catalog Number: (89165-996)

Supplier: Enzo Life Sciences

Description: Membrane Potential Detector

Catalog Number: (89166-040)

Supplier: Enzo Life Sciences

Description: Amine reactive dye

Catalog Number: (89141-064)

Supplier: Enzo Life Sciences

Description: For the quantitative determination of progesterone in culture supernatants, serum, and saliva from any species

Catalog Number: (89161-032)

Supplier: Enzo Life Sciences

Description: Calcineurin substrate

Catalog Number: (89165-840)

Supplier: Enzo Life Sciences

Description: Bio-7-dATP (Biotin-7-2’-deoxyadenosine-5’-triphosphate) can replace dATP in reactions in which it serves as a substrate for E. coli DNA polymerase (holoenzyme and Klenow fragment), T4 and Taq DNA polymerases, reverse transcriptase (from AMV and M-MuLV) and terminal transferase.

Catalog Number: (89152-516)

Supplier: Enzo Life Sciences

Description: Antihelmintic agent.

Catalog Number: (89160-348)

Supplier: Enzo Life Sciences

Description: Fluor de Lys®-HDAC8 is a fluorogenic, diacetylated peptide substrate for HDAC8 (histone deacetylase-8). Based on residues 379-382 of p53 (Arg-His-Lys(Ac)-Lys(Ac)), a site of regulatory acetylation by the p300 and CBP acetyltransferases (lysines 381, 382), it was the best for HDAC8 from among a panel of substrates patterned on p53, histone H3 and histone H4 acetylation sites. Fluor de Lys®-HDAC8 is deacetylated by HDAC8 at a rate of more than 10-fold that of the acetylated lysine substrate, Fluor de Lys® (BML-KI104; substrates both at 100 µM). Although named because of HDAC8’s preference for it, it is also an excellent substrate for SIRT1 (BMl-SE239; 5x the rate of BML-KI104 at 25 µM, 0.5 mM NAD+), SIRT2 and HeLa Nuclear Extract (BML-KI140; 3x KI-104 rate, 25 µM). Must be used in conjunction with Fluor de Lys® Developer II (BML-KI176). Sufficient for 100-200 assays of human recombinant HDAC8 (BML-SE145; 1 U/well, 50-100 µM substrate).

Catalog Number: (89163-764)

Supplier: Enzo Life Sciences

Description: Produced in<i> E. coli.</i>

Catalog Number: (89152-398)

Supplier: Enzo Life Sciences

Description: Na+ channel blocker

Catalog Number: (89162-330)

Supplier: Enzo Life Sciences

Description: Studies have demonstrated that PR39, a proline/arginine rich 39 amino acid antibacterial peptide originally derived from porcine bone marrow, exhibits a broad spectrum of biological activities, including the ability to induce angiogenesis and to limit inflammatory damage in a variety of animal models. The angiogenic effect is in part explained by the ability of PR39 to inhibit proteasome-dependent degradation of the transcription factor HIF-1a, while anti-inflammatory activity is associated with inhibition of IκBα degradation that in turn prevents activation of NFκB-dependent gene expression. The activities of PR39 reside in the N-terminal portion of the molecule encompassed by PR11. The most recent findings have demonstrated that PR39 is a non-competitive and reversible inhibitor of the proteasome function, which is achieved by a unique allosteric mechanism allowing for specific inhibition of degradation of selected proteins without affecting total proteasome-dependent proteolysis. A proline-arginine-rich 11 amino acid peptide derived from the naturally occurring peptide antibiotic PR39. PR39 has been shown to act as an inhibitor of both 20S and 26S proteasomes with proposed selectivity for the inhibition of the degradation of IκBα, HIF-1a and certain other proteins. PR39 has been reported to inhibit the proteasomal degradation of IκBα without effecting overall proteasome activity, or degradation of p21Cip1/Waf1 and c-fos, cell-cycle genes regulated by proteasome-dependent degradation. In vitro studies have demonstrated PR39 to be an efficient inhibitor of all three activities of the 20S proteasome. Unlike MG132 and lactacystin, long-term exposure to PR39 shows little toxicity or induction of HSP-70. In mouse models of myocardial infarction it has been shown that infusion with PR11 results in a significant reduction of myocardial infarct size. PR39, PR11 and related peptides may therefore provide novel means to regulate cellular function and the control of NF-κB-dependent gene expression for therapeutic purposes.

Catalog Number: (89163-878)

Supplier: Enzo Life Sciences

Description: Produced in yeast. Recombinant human granzyme B (aa 21-247).

Catalog Number: (89165-820)

Supplier: Enzo Life Sciences

Description: The procedure for labeling of DNA probes with a polynucleotide "tail" containing hapten-labeled nucleotides was developed by Enzo. In such terminal labeling reactions, terminal transferase catalyzes the addition of nucleotides to any 3'-OH terminus in a template independent manner. This rapid and convenient nonradioactive labeling procedure is free of any sequence bias that is normally observed in random priming or nick translation reactions.